190898-77-2

Basic information

• Product Name: 2,1-Benzisoxazole, 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-
• CAS NO: 190898-77-2
• Molecular Formula: C22H15Cl2NO3
• Molecular Weight: 412.272
• Mol File: 190898-77-2.mol

Chemical Properties

• CAS DataBase Reference: 2,1-Benzisoxazole, 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,1-Benzisoxazole, 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-(190898-77-2)
• EPA Substance Registry System: 2,1-Benzisoxazole, 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-(190898-77-2)

Safety Data

• Hazardous Substances Data: 190898-77-2(Hazardous Substances Data)

Upstream product

• 7497-60-1 (4-Chlorophenyl)(4-nitrophenyl)methanone 
• 1529-41-5 3-chloro-benzeneacetonitrile 
• 190898-64-7 2-(4-Chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane 
• 766-84-7 3-chloro-benzonitrile 

Downstream Products

• 432553-06-5 2-bromo-N-[2-[(3-chlorophenyl)hydroxymethyl]4-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]phenyl]-acetamide 
• 215034-80-3 2,2,2-trichloro-N-{2-(3-chloro-benzoyl)-4-[2-(4-chloro-phenyl)-[1,3]dioxolan-2-yl]-phenyl}-acetamide 
• 432552-78-8 5-(3-chlorophenyl)-7-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1,5-dihydro-4,1-benzothiazepin-2(3H)-one 
• 432552-79-9 5-(3-chlorophenyl)-7-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1,5-dihydro-1-methyl-4,1-benzoxazepin-2(3H)-one 
• 432552-87-9 7-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-5-(3-chlorophenyl)-1,5-dihydro-1-methyl-4,1-benzothiazepin-2(3H)-one 
• 432552-82-4 5-(3-chlorophenyl)-7-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1,5-dihydro-1-methyl-4,1-benzothiazepin-2(3H)-one 
• 215034-62-1 4-(3-chloro-phenyl)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-1-methyl-1H-quinazolin-2-one 
• 215034-65-4 6-[chloro-(4-chloro-phenyl)-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-chloro-phenyl)-1-methyl-1H-quinazolin-2-one 
• 432553-32-7 7-[chloro(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-5-(3-chlorophenyl)-1,5-dihydro-1-methyl-4,1-benzothiazepin-2(3H)-one 
• 432552-77-7 5-(3-chlorophenyl)-7-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1,5-dihydro-4,1-benzoxazepin-2(3H)-one 
• 192187-40-9 (+/-)-[2-amino-5-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]phenyl](3-chlorophenyl)methanone 
• 432553-05-4 4-amino-α3-(3-chlorophenyl)-α1-(4-chlorophenyl)-α1-(1-methyl-1H-imidazol-5-yl)-1,3-benzenedimethanol 
• 215034-81-4 4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2(1H)-quinazolinone 
• 192187-39-6 (+/-)-3-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)-2,1-benzisoxazole-5-methanol 

Relevant articles and documents

Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA

The discovery that post-translational farnesylation of Ras oncoprotein was an essential step in exercising its biological effect led to the design of farnesyl protein transferase inhibitors (FTIs) in order to control growth of tumors bearing Ras mutations. Pre-clinical studies on murine models have confirmed their inhibitory effect on tumor growth and enabled clinical development. R115777 (ZARNESTRA) is currently undergoing clinical evaluation and recent studies have confirmed its antitumor potential and low toxicity. We wish to describe here the chemical synthesis routes that our group have developed to access ZARNESTRA. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

The evaluation of structure-activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described.

Farnesyltransferase inhibiting quinazolinones

This invention concerns compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1and R2eac

Farnesyl transferase inhibiting 2-quinolone derivatives

The present invention is concerned with compounds of formula (I), STR1 the stereoisomeric forms thereof and the pharmaceutically acceptable acid or base addition salts thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R